Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,510.00
Bid: 12,524.00
Ask: 12,526.00
Change: 118.00 (0.95%)
Spread: 2.00 (0.016%)
Open: 12,468.00
High: 12,556.00
Low: 12,434.00
Prev. Close: 12,392.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

GLOBAL MARKETS-Stocks soured by Wall Street sell-off and 'vaccine nationalism'

Thu, 28th Jan 2021 09:11

* Asian stock markets : https://tmsnrt.rs/2zpUAr4

* Easyjet highlights pain of airlines during lockdown

* Talk of distressed selling by hedge funds as shorts
squeezed

* Dollar gets safe-haven bid as euro backtracks

By Huw Jones

LONDON, Jan 28 (Reuters) - Shares wiped out their gains in
Europe for the year early on Thursday, soured by a sell-off on
Wall Street, no end in sight to pandemic lockdowns and a squeeze
in short positions.

The pan-European STOXX benchmark was down 1.8% at
395.77 points, its lowest since December. London, Paris
and Frankfurt all fell.

"The initial optimism of early this year is starting to
dissipate because of the prospects of tighter pandemic
restrictions for longer, and concerns over 'vaccine
nationalism'," said Michael Hewson, chief market analyst at CMC
Markets.

The European Union, locked in a public spat with vaccine
producer AstraZeneca, wants a shortfall in the company's
supplies to the bloc topped up from production in Britain.

Easyjet shares fell 2.3% after the airline warned it
would fly no more than 10% of 2019's capacity, highlighting the
plight of sectors hit by lengthy lockdowns.

The move by investors into "reflation" trades at the start
of the year on then-brighter growth prospects now looked
premature, analysts said.

"Amid concerns about the speed of vaccine distribution and
the COVID-19 impact on economic growth recovery, cyclical credit
looks most likely to underperform," UniCredit analysts said.

Wall Street on Wednesday suffered its biggest one-day
percentage drop in three months as the S&P500 index and Nasdaq
Composite fell 2.6%.

Some pointed a finger at U.S. retail investors who had
forced a massive squeeze on hedge funds that held short
positions in stocks such as GameStop.

"We could see much more choppiness and much more volatility.
We have a bit of a perfect storm heading into the month end,
which is weighing on equity markets, but I don't think at the
moment we are in a place where it's going to come crashing off,"
Hewson said.

On the data front, analysts said the focus will be on German
inflation figures and fourth-quarter U.S. economic growth.

Yields on the 10-year U.S. Treasury bond fell
below 1% for the first time in three weeks overnight in a
further sign of a shrinking demand for risk.

ASIA WEAKER

Asian shares slid on Thursday while the safe-haven dollar
rallied as Wall Street's sell-off and delays in coronavirus
vaccines provided an excuse to book profits on recent gains.

MSCI's broadest index of Asia-Pacific shares outside Japan
fell 2%, with valuations looking stretched after
the index rose more than 6% just this month.

Japan's Nikkei fell 1.5%, its sharpest drop since
October, and Chinese blue chips lost 2.7% as liquidity
tightened before the Lunar New Year holidays.

South Korea fell 1.7%, led by losses in Samsung
after it reported earnings.

Even the tech darlings were not immune. Facebook
dropped despite reporting earnings well above expectations.
Apple Inc also handily beat forecasts, but its shares
lost 3% after the bell.

Dealers noted the market had focused more on a downbeat
economic outlook from the Federal Reserve overnight than on its
pledge of continued policy support.

The safe-haven U.S. dollar gained, with its index up at
90.771 from a January low of 89.206.

The euro fell to $1.2093 amid reports the European
Central Bank felt markets were under-pricing the risk of more
rate cuts.

The bounce in the dollar kept gold prices soft around $1,837
an ounce.

Global demand concerns restrained oil prices despite a drop
in U.S. crude stocks. U.S. crude fell 34 cents to $52.51
a barrel. Brent crude futures dropped to $55.50.

(Additional reporting by Alwyn Scott; editing by Christian
Schmollinger, Ana Nicolaci da Costa, Larry King)

More News
17 Nov 2023 12:00

LONDON MARKET MIDDAY: Stocks shrug off downbeat UK retail sales

(Alliance News) - Stock prices in London were up at midday on Friday, as a week of favourable data as far as inflation goes gave investors a reason to overlook disappointing UK retail sales figures.

Read more
17 Nov 2023 09:03

LONDON MARKET OPEN: Stocks up despite UK retail sales growth miss

(Alliance News) - Stock prices in London opened higher on Friday, despite weaker-than-expected October retail sales figures for the UK.

Read more
17 Nov 2023 08:31

TOP NEWS: US approves AstraZeneca's Truqap for form of breast cancer

(Alliance News) - AstraZeneca PLC on Friday said that the US Food & Drug Administration approved its drug Truqap in combination with Faslodex to treat patients with an advanced form of breast cancer.

Read more
17 Nov 2023 07:58

LONDON BRIEFING: UK retail sales fall; AstraZeneca gets US approval

(Alliance News) - Stock prices in London are still set to open higher on Friday, despite October retail sales figures for the UK disappointing shortly before the opening bell.

Read more
17 Nov 2023 07:16

AstraZeneca gets US approval for breast cancer treatment

(Sharecast News) - AstraZeneca's 'Truqap', or capivasertib, in combination with 'Faslodex', or fulvestrant, has secured approval from the US Food and Drug Administration (FDA) for specific breast cancer treatments, the company announced on Friday.

Read more
14 Nov 2023 10:51

TOP NEWS: AstraZeneca Imfinzi fails to meet endpoint in cancer trial

(Alliance News) - AstraZeneca PLC on Tuesday said the Pacific-2 phase III trial for Imfinzi as an early treatment lung cancer immunotherapy treatment administered with chemoradiotherapy, did not meet its primary endpoint.

Read more
14 Nov 2023 09:22

AstraZeneca's latest lung cancer trial fails its primary endpoint

(Sharecast News) - AstraZeneca announced on Tuesday that its 'PACIFIC-2' phase three trial for Imfinzi, or durvalumab, concurrently administered with chemoradiotherapy (CRT), did not achieve its primary endpoint of progression-free survival compared to CRT alone.

Read more
13 Nov 2023 09:45

LONDON BROKER RATINGS: Diageo gets price target cuts; JPMorgan ups M&G

(Alliance News) - The following London-listed shares received analyst recommendations Monday morning:

Read more
9 Nov 2023 15:02

London close: Stocks gain as investors await Powell speech

(Sharecast News) - London's stock markets were buoyant at the close of trading on Thursday, influenced by Chinese inflation data, a substantial influx of corporate news, and a speech from the Fed chair later in the global day.

Read more
9 Nov 2023 12:06

LONDON MARKET MIDDAY: FTSE up despite higher for longer US rates fear

(Alliance News) - European equities were on the up on Thursday, despite lingering US interest rate worries and poor China data.

Read more
9 Nov 2023 11:02

Lancashire Holdings declares special dividend after strong year so far

(Alliance News) - Lancashire Holdings Ltd on Thursday said it approved a capital return of up to USD169 million, and it reported rising gross premiums written for the year-to-date.

Read more
9 Nov 2023 09:23

TOP NEWS: AstraZeneca ups guidance; inks licence deal for obesity drug

(Alliance News) - AstraZeneca PLC on Thursday announced that it signed a contract for an obesity drug as it reported a higher pretax profit in the third quarter of 2023, boosted by cancer drug conjugate Enhertu.

Read more
9 Nov 2023 08:57

LONDON MARKET OPEN: FTSE 100 kicks off day with cautious gain

(Alliance News) - London's FTSE 100 struggled for direction early Thursday, with a mixed slate of corporate updates, US interest rate worries and underwhelming China data preventing it from making more confident progress in early trade.

Read more
9 Nov 2023 07:48

LONDON BRIEFING: AstraZeneca ups outlook but S4 Capital cuts

(Alliance News) - London's FTSE 100 is set for another downbeat start to the day, with more hawkish comments from US central bankers and tepid data out of China doing little to lift the mood.

Read more
9 Nov 2023 07:18

AstraZeneca hikes guidance after strong third quarter

(Sharecast News) - AstraZeneca released its financial results for the third quarter and first nine months of 2023 on Thursday, hiking its full-year guidance on the back of a robust performance and momentum in several segments.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.